Osaka, Japan, December 1, 2017 — Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) announced today that Takeda Pharmaceutical Real Estate Company (“Takeda Real Estate”), a wholly-owned subsidiary of Takeda, has signed an agreement with Takashimaya Company Limited (Head Office: Chuo-ku, Osaka) for the sale of the Tokyo Takeda Building (Takeda’s current Tokyo headquarters), and the Takeda Shin-Edobashi Building.
The sale price is 49.5 billion yen and Takeda plans to book a pre-tax gain of approximately 39 billion yen in the second half of fiscal year 2018. Unlocking cash and investing for profitable growth is a key driver of Boost Profitability, one of Takeda’s key priorities. The transfer of the real estate will be completed by the end of March, 2019.
The Tokyo Takeda Building was completed in 1966 as Takeda’s Tokyo Branch/Sales Office to accommodate the expansion of business operations. In 1984, the building also became Takeda’s Tokyo Headquarters. Takeda is currently constructing a new Tokyo Headquarters, the Shin-Tokyo Takeda Building* (provisional name), in Nihonbashi-Honcho, Tokyo and plans to relocate there upon completion in the spring of 2018.
* For more information about the construction of the Shin-Tokyo Takeda Building, please see Takeda’s press release issued on February 6, 2015.
+81 (0) 3-3278-2095